Rapamune Labeling Will Reflect “Excess Rate Of Death” In Liver Transplants
Executive Summary
Labeling for Wyeth's immunosuppressant drug Rapamune will be updated to reflect "an excess rate of death and graft loss" when used after liver transplant
You may also be interested in...
Wyeth Rapamune Boxed Warning On Lung Transplants Added To Labeling
Wyeth has added a boxed warning to Rapamune labeling to reflect an increased incidence of bronchial anastomotic dehiscence in de novo lung transplant patients administered the immunosuppressant
Wyeth Rapamune Boxed Warning On Lung Transplants Added To Labeling
Wyeth has added a boxed warning to Rapamune labeling to reflect an increased incidence of bronchial anastomotic dehiscence in de novo lung transplant patients administered the immunosuppressant
Wyeth Rapamune May Need New U.S. Trial For Cyclosporine-Free Regimen
Wyeth's proposed Rapamune cyclosporine-free regimen may need another U.S. study before approval, FDA's Antiviral Drugs Immunosuppressive Subcommittee Advisory Committee indicated at its Jan. 24 meeting